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Background: Age is an important risk factor for breast cancer, but previous data has been contradictory on whether
patient age at diagnosis is also related to breast cancer survival. The present study evaluates age at diagnosis as a
prognostic factor for breast cancer on a large cohort of patients at a single institution.
Methods: All 4,453 women diagnosed with breast cancer in Malmö University Hospital, Sweden between 1961 and
1991 were followed up on for 10 years with regards to breast cancer-specific mortality (BCSM) in different age groups.
Corresponding relative risks (RR), with 95% confidence intervals, were obtained using Cox’s proportional hazards analysis.
All analyses were adjusted for potential confounders and stratified for axillary lymph node involvement (ALNI) and
diagnostic period.
Results: As compared to women aged 40 to 49 years, those who were aged under 40 (RR: 1.40; 95% CI: 1.04 to 1.88)
and 80 or more years (RR: 1.80; 95% CI: 1.45 to 2.25) had a statistically significant higher 10-year mortality rate. When
adjusted for potential confounders, including stage at diagnosis, the associations only remained statistically significant
for women aged 80 years or more. In the analyses stratified on ALNI, ALNI-negative women under 40 years had a
statistically significant higher five-year mortality rate (RR: 2.65; 95% CI: 1.23 to 5.70). In the analyses stratified on
diagnostic period, the positive association between women aged under 40 or aged 80 or more years and high
BCSM rate remained, with statistically significant results for women aged 80 years or more in all periods.
Conclusions: Women under 40 years of age had a poor prognosis, and this association was strongest among
young women with axillary lymph node negative breast cancer. An age of 80 years or more was a prognostic
factor for poor survival, independent of stage at diagnosis and diagnostic period.
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Age is an important risk factor for breast cancer, but it
has also been suggested that patient age at diagnosis is
related to breast cancer survival [1,2]. It has been pro-
posed that young and old age may be adverse prognostic
factors, but data is conflicting [3-5]. As breast cancer is
the most common malignancy in women under 40 years
of age and approximately one third of breast cancer is
diagnosed in women aged 70 years and older, it is im-
portant to clarify the association between age at diagno-
sis and breast cancer survival [2]. Previous data has been* Correspondence: jasmine.brandt@med.lu.se
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unless otherwise stated.contradictory on whether the poor prognosis of young
women exists in all stages, or only in women with small
tumors and without axillary lymph node involvement
(ALNI) [6-11]. Regarding the elderly, some studies have
shown elderly women to have a poor outcome [5,12,13],
whereas a few studies did not find an association [4,14]
and one large study even found elderly women with
ALNI-negative tumors to have a favorable outcome [15].
A potential reason as to why previous data has been
conflicting may be that different cut-offs for age, as well
as wide age groups have been used. Also, several studies
have included only young or elderly women instead of
all age categories. Furthermore, many previous studies
have either consisted of small datasets or included sev-
eral institutions. Follow-up time has in many studies also
varied within the cohort, with the possible result thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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spuriously low mortality rates, due to accumulated
person-years.
The present cohort consists of a large unselected ma-
terial of all women diagnosed with invasive breast cancer
at a single institution in Sweden between 1961 and 1991.
A total number of 4,453 cases were included and infor-
mation was collected on clinical factors and tumor char-
acteristics such as tumor size, ALNI, and distant
metastasis [16]. The data has been followed up on
through record-linkage with the Swedish Cause of Death
Registry, and the entire cohort had the same follow-up
time of 10 years. The large size of the cohort allowed
the use of narrow age groups in the analyses, to study
development over time, and stratification for other prog-
nostic factors and diagnostic period.
The aim of the present study was to evaluate patient
age at diagnosis as a prognostic factor for breast cancer
on a large dataset at a single institution, and to examine
the role of the factors included in stage at diagnosis
(size, ALNI, and distant metastasis) and diagnostic
period on this potential association.Methods
The Malmö Breast Cancer Database
The study cohort consists of all cases of invasive female
breast cancer in Malmö, Sweden, diagnosed between 1
January 1961 and 31 December 1991. They were all
treated at the same institution, Malmö University
Hospital, and no referrals were made to or from the hos-
pital for patients with breast cancer. All residents in
Sweden are registered by a unique 10-digit ID number.
Breast cancer patients were identified by review of clin-
ical notes and record-linkage with the Swedish Cancer
Registry, forming the basis of the Malmö Breast Cancer
Database. This was all completed by one surgeon, who
also validated all breast cancer diagnoses by reviewing
histological material, X-ray examinations, and medical
records [16]. The present study was approved by the re-
gional ethical committee in Lund, Sweden (approval
number: LU-Dnr 615/2004).Clinical data and tumor characteristics
The surgeon identifying the cases and constructing the
database also collected data regarding date of diagnosis,
menopausal status, height, weight, parity, laterality,
tumor location, and distant metastases through medical
records and the Swedish Cancer Registry. Information
concerning tumor size, histological type, and ALNI was
retrieved from histopathological examinations. Tumor
type was classified using a modification of the World
Health Organization (WHO) classification as proposed
by Linell et al. [17]. ALNI was divided into positive,negative, or unknown if no axillary dissection had been
performed.
Age at diagnosis
Age at diagnosis was obtained through a record-linkage
between the Swedish Population Registry and the
Swedish Cancer Registry. This information was available
for all cases in the present study. The women were sub-
sequently divided into six age groups: <40 years, 40 to
49 years, 50 to 59 years, 60 to 69 years, 70 to 79 years,
and ≥80 years at the time of diagnosis.
Follow-up
Follow-up was limited to 10 years following diagnosis.
Two important reasons lay behind this decision; first,
most recurrences and deaths from breast cancer occur
within 10 years and second, patients diagnosed in the
first diagnostic period accumulated a large number of
person-years as compared to patients in later diagnostic
periods. This would lead to spuriously low mortality
rates for patients diagnosed during the first and second
periods. To identify all deceased patients during the
follow-up period, the cases’ ID-numbers were linked to
the Swedish Cause of Death Registry (up until 31
December 2007), which contains information on date of
death and underlying cause of death, as well as subor-
dinate causes of death. The primary endpoint of this
study was breast cancer as the underlying cause of
death.
Study population
A total of 4,453 women were diagnosed with breast cancer
in Malmö during the study period (1961 to 1991). Out of
these, 111 women were excluded as they obtained their
breast cancer diagnosis at autopsy, 10 women were ex-
cluded due to missing information on all variables, 109
women were excluded because they had a previous diag-
nosis of breast cancer, and 104 women were excluded due
to bilateral carcinomas. Consequently, the final study
population consisted of 4,119 women.
Statistical methods
The six age groups were compared concerning clinical
factors and tumor characteristics. For the subsequent
analyses the age categories were evaluated in relation to
both a five-year and 10-year follow-up period. The time
scale for the study was date of diagnosis until death or
until end of the follow-up period, giving each individual
a potential maximum of five and 10 years in the ana-
lyses, respectively. Missing values in covariates were
coded as a separate category. Breast cancer-specific
mortality (BCSM) rate was calculated per 10,000 person-
years in different categories of age. Corresponding rela-
tive risks (RR) with 95% confidence intervals (CI) were
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proportional hazards assumption was confirmed using a
log-minus-log plot. Women aged 40 to 49 years at diag-
nosis, were used as the reference. The reason for select-
ing this age category was that the youngest age group
contained only 164 subjects, along with the fact that it
has been suggested that the potential association be-
tween age and survival is bi-modal [13]. All Cox analyses
were subsequently adjusted for factors making up tumor
stage; tumor size, ALNI, and distant metastases. In a
third model, all analyses were also adjusted for other po-
tential prognostic factors. First, by adjusting for one fac-
tor at a time and secondly, for all of the potential
prognostic factors simultaneously. The only variable not
adjusted for was menopausal status, since nearly all
women in the two youngest age groups were premeno-
pausal, whereas all patients in the three oldest age
groups were postmenopausal. Subsequently, all analyses
were stratified for ALNI, as well as for diagnostic period,
in order to reveal whether or not delayed diagnosis
could have affected the results.
It has been suggested that women under 35 years of
age may have a poor prognosis [18]. This was examined
in a sensitivity analysis, subdividing women under
40 years of age into two groups; under 35 years and 35
to 39 years. This analysis used the same reference group
(40 to 49 years).
Results
Patient characteristics with reference to age at diagnosis
Clinical factors and tumor characteristics of the six age
groups are shown in Table 1. Distant metastasis at the
time of diagnosis was more common with increasing
age. There was considerably more missing data for the
oldest age category (≥80 years) concerning axillary
lymph node status. It was more common for older
women to have been regarded as unsuitable for surgery,
and it was also less common for these women to have
undergone an axillary dissection.
Age at diagnosis in relation to survival
Young age (<40 years) was positively associated with a
high BCSM in both the five-year follow-up period and in
the 10-year follow-up period, although it was only statis-
tically significant in the 10-year follow-up period
(Table 2). However, the association disappeared when
adjusted for stage and other potential prognostic factors.
The two oldest age categories, 70 to 79 and ≥80 years,
had a statistically significant higher BCSM as compared
to the reference group in both the five- and 10-year
follow-up period. Women aged 80-years-old or more
displayed the worst outcome, and this association
remained statistically significant after adjustment for all
potential confounders.When adjusting for confounders one by one, the two
factors that affected the results the strongest were
ALNI and tumor size. ALNI decreased the youngest
age category’s RR from 1.34 (95% CI: 0.94 to 1.92) to
0.97 (95% CI: 0.74 to 1.27) and the oldest age category’s
RR from 1.93 (95% CI: 1.50 to 2.48) to 1.09 (95% CI:
0.78 to 1.51) in the five-year follow-up period.
In the sensitivity analysis, women under 35 years of
age (53 women) had an RR of 1.36 (95% CI: 0.77 to 2.42)
and women 35 to 39 years (111 women) had an RR of
1.36 (95% CI: 0.89 to 2.06). In the 10-year follow-up
period, women aged 35 to 39 had a statistically signifi-
cant RR of 1.50 (95% CI: 1.07 to 2.11), whereas the result
for women under 35 did not reach statistical signifi-
cance, with an RR of 1.23 (95% CI: 0.75 to 2.02).
Age at diagnosis and survival in relation to axillary lymph
node involvement
Young age (<40 years) was associated with a high BCSM
among ALNI-negative women in the five- and 10-year
follow-up periods (Table 3, Figure 1). The association
was statistically significant in the five-year follow-up
period with an RR of 2.65 (95% CI: 1.23 to 5.70). Ten-year
BCSM rates were also high but were not statistically sig-
nificant, with an RR of 1.69 (95% CI: 0.92 to 3.09).
Following adjustments for all potential factors, the point
estimate among ALNI-negative women followed up on
for five years was still high, but it did not reach statis-
tical significance.
Women aged 70 to 79 years who were ALNI-negative
also displayed a high BCSM. The oldest age group
(≥80 years) had a high BCSM among both ALNI-
negative and ALNI-positive women throughout both the
five- and 10-year follow-up periods.
In the sensitivity analysis, ALNI-negative women aged
35 to 39 years (111 women) displayed a statistically sig-
nificant RR of 3.50 (95% CI: 1.59 to 7.70) and women
under 35 years (53 women) an RR of 0.82 (95% CI: 0.11
to 6.17) in the five-year follow-up period. Results were
similar in the 10-year follow-up period.
Age at diagnosis and survival in relation to diagnostic
period
In the results stratified for diagnostic period, young age
(<40 years) continued to be related to poor prognosis
throughout the diagnostic periods in the five-year
follow-up, although the results were not statistically
significant (Table 4). The oldest age category (≥80 years)
displayed the highest BCSM in all diagnostic periods.
The results were similar in the 10-year follow-up for all
age categories.
Figure 2 displays the absolute risks, measured as
BCSM per 10,000 person-years, which can also be found
in Table 4. Mortality rates decreased for all age groups
Table 1 Distribution of age at diagnosis in relation to patient characteristics, tumor characteristics, and surgical
treatment
Factor Age at diagnosis (years)
<40 40-49 50-59 60-69 70-79 ≥80
(n = 164) (n = 630) (n = 886) (n = 1062) (n = 818) (n = 559)
Column percenta
Time of diagnosis
1961-1970 31 34 29 26 23 20
1971-1980 27 34 39 36 35 32
1981-1991 42 33 32 38 42 48
Menopausal status
Premenopausal 97 90 21 0 0 0
Postmenopausal 3 10 79 100 100 100
Body Mass Index
<20 16 11 6 4 5 6
20 - <25 48 43 37 28 26 17
25 - <30 9 16 20 26 26 17
≥30 2 4 8 11 10 5
Missing 25 26 29 31 33 55
Parity (number of children)
Nullipara 23 20 21 25 28 28
1 26 25 27 25 22 16
2 32 32 31 25 19 12
3 14 15 12 12 13 7
≥4 3 3 5 7 9 10
Unknown 2 5 4 6 9 27
Size of primary tumor (millimeters)
<5 2 2 4 2 2 1
5 - ≤10 9 12 16 15 10 7
10 - ≤20 30 29 30 34 33 25
20 - ≤50 31 25 23 26 31 33
>50 2 3 3 3 4 6
Missing 26 29 24 20 20 28
Histological type
Tubular 4 8 8 6 8 4
Tubulo-ductal 9 13 14 18 17 15
Comedo 49 31 28 26 25 23
Lobular 4 10 8 9 9 8
Invasive, variable, unknown 14 12 12 11 11 22
Invasive, type not assessed 20 26 30 30 30 28
Tumor location
Upper inner quadrant 19 15 18 18 18 16
Lower inner quadrant 7 8 7 7 7 6
Upper outer quadrant 42 43 43 42 41 38
Lower outer quadrant 12 13 11 13 12 11
Central 10 14 14 14 15 18
Missing 10 7 7 6 7 11
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Table 1 Distribution of age at diagnosis in relation to patient characteristics, tumor characteristics, and surgical
treatment (Continued)
Axillary lymph node status
Negative 51 50 49 55 46 22
Positive 46 44 42 36 34 22
Unknown 3 6 9 9 20 56
Distant metastasis at diagnosis
No 99 97 95 94 91 90
Yes 1 3 5 6 9 10
Type of surgery
Mastectomy 85 87 84 81 84 64
Partial mastectomy/local excision 15 13 14 16 9 14
Inoperable 0 0 0 3 7 22
Axillary dissection
Yes 98 94 92 91 81 44
No 2 6 6 6 12 33
Inoperable 0 0 2 3 7 22
N = number of patients in each age category.
a Due to some missing values, percentages do not always add to 100%.


















<40 164 722 40 (45) 554 1.34 (0.94-1.92) 0.95 (0.72-1.25) 0.85 (0.65-1.12)
40-49 630 2,846 117 (133) 411 1.00 1.00 1.00
50-59 886 3,801 195 (226) 513 1.25 (0.99-1.57) 1.08 (0.88-1.33) 1.07 (0.87-1.31)
60-69 1,062 4,559 204 (283) 448 1.09 (0.87-1.36) 1.02 (0.83-1.26) 1.08 (0.87-1.34)
70-79 818 3,146 177 (330) 563 1.36 (1.08-1.72) 1.02 (0.82-1.28) 1.15 (0.91-1.45)
≥80 559 1,607 130 (378) 809 1.93 (1.50-2.48) 1.32 (0.96-1.83) 1.53 (1.08-2.16)
All 4,119 16,681 863 (1395) 517
10-year
follow-up
<40 164 1,251 59 (66) 472 1.40 (1.04-1.88) 0.96 (0.77-1.20) 0.89 (0.71-1.12)
40-49 630 5,173 171 (193) 331 1.00 1.00 1.00
50-59 886 6,817 276 (337) 405 1.22 (1.01-1.47) 1.11 (0.94-1.32) 1.08 (0.91-1.28)
60-69 1,062 8,017 283 (445) 353 1.05 (0.87-1.27) 1.06 (0.89-1.26) 1.08 (0.90-1.29)
70-79 818 5,034 240 (543) 477 1.37 (1.12-1.66) 0.99 (0.82-1.21) 1.10 (0.90-1.35)
≥80 559 2,168 147 (497) 678 1.80 (1.45-2.25) 1.44 (1.07-1.93) 1.61 (1.18-2.20)
All 4,119 28,460 1,176 (2081) 413
CI = Confidence Intervals.
aBreast cancer-specific mortality per 10,000 person-years.
bAdjusted for tumor size, axillary lymph node status, and distant metastasis.
cAdjusted for diagnostic period, BMI, parity, tumor size, axillary lymph node status, histological type, tumor location, and distant metastasis.
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Table 3 Age at diagnosis in relation to breast cancer-specific mortality with stratification for axillary lymph node stat
Axillary lymph node status Age at diagnosis (years) Subjects Person-years Breast cancer deaths
(all deaths)






Negative 5- year follow-up <40 84 399 11 (12) 276 2.65 (1.23-5.70) 2.40 (1.11-5.17) 1.91 (0.88-4.19)
40-49 313 1,531 16 (23) 105 1.00 1.00 1.00
50-59 434 2,052 32 (48) 156 1.50 (0.82-2.73) 1.68 (0.92-3.06) 1.64 (0.90-3.02)
60-69 579 2,761 29 (65) 105 1.01 (0.55-1.86) 0.92 (0.49-1.71) 0.87 (0.46-1.64)
70-79 373 1,661 29 (81) 175 1.70 (0.92-3.12) 1.50 (0.81-2.80) 1.35 (0.71-2.58)
≥80 123 488 10 (57) 205 2.03 (0.92-4.47) 1.69 (0.76-3.78) 1.88 (0.82-4.30)
All 1,906 8,890 127 (286) 143
10-year follow-up <40 84 741 15 (18) 202 1.69 (0.92-3.09) 1.53 (0.84-2.81) 1.29 (0.70-2.38)
40-49 313 2,912 35 (47) 120 1.00 1.00 1.00
50-59 434 3,881 58 (90) 149 1.25 (0.82-1.90) 1.38 (0.90-2.10) 1.44 (0.94-2.20)
60-69 579 5,119 57 (143) 111 0.93 (0.61-1.41) 0.89 (0.58-1.36) 0.90 (0.58-1.38)
70-79 373 2,860 60 (187) 210 1.75 (1.15-2.66) 1.55 (1.01-2.37) 1.51 (0.97-2.35)
≥80 123 714 13 (98) 182 1.54 (0.81-2.91) 1.25 (0.66-2.38) 1.44 (0.74-2.78)
All 1,906 16,228 238 (583) 147
Positive 5- year follow-up <40 75 301 28 (32) 930 1.19 (0.78-1.82) 1.33 (0.87-2.04) 1.07 (0.69-1.66)
40-49 274 1,141 89 (95) 780 1.00 1.00 1.00
50-59 376 1,498 130 (139) 868 1.12 (0.85-1.46) 1.23 (0.94-1.61) 1.29 (0.98-1.70)
60-69 383 1,526 128 (158) 839 1.08 (0.82-1.41) 1.20 (0.92-1.58) 1.30 (0.98-1.72)
70-79 283 1,059 86 (134) 812 1.05 (0.78-1.41) 1.11 (0.82-1.50) 1.21 (0.88-1.66)
≥80 124 383 47 (81) 1,227 1.60 (1.13-2.29) 1.38 (0.96-1.98) 1.68 (1.14-2.25)
All 1,515 5,908 508 (639) 860
10-year follow-up <40 75 472 42 (46) 890 1.39 (0.98-2.00) 1.55 (1.09-2.21) 1.34 (0.94-1.93)
40-49 274 1,954 121 (128) 619 1.00 1.00 1.00
50-59 376 2,530 177 (198) 700 1.13 (0.90-1.42) 1.25 (0.99-1.57) 1.26 (1.00-1.60)
60-69 383 2,461 174 (228) 707 1.12 (0.89-1.42) 1.25 (0.99-1.58) 1.27 (1.00-1.63)
70-79 283 1,580 112 (217) 709 1.10 (0.85-1.42) 1.14 (0.88-1.48) 1.22 (0.93-1.60)
≥80 124 523 53 (106) 1,013 1.54 (1.11-2.13) 1.30 (0.93-1.81) 1.61 (1.13-2.28)
All 1,515 9,520 679 (923) 713
CI = Confidence Intervals.
a Breast cancer-specific mortality per 10,000 person-years.
bAdjusted for tumor size and distant metastasis.
































Figure 1 Age at diagnosis in relation to breast cancer-specific mortality with stratification for axillary lymph node involvement (ALNI);
five-year follow-up period.
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was most apparent for women aged 50 to 59 and 60 to
69-years-old. Being diagnosed between 1981 and 1991
was associated with the best prognosis for all age categories,
except for the youngest age category and the reference
category, which instead had a lower BCSM in the diagnos-
tic period 1971 to 1980. Women aged 80 years or more
continued to show a significantly higher absolute risk
compared to all other age categories throughout the diag-
nostic periods.
Discussion
In this study, young (<40 years) and old (≥80 years) age
was positively associated with a high BCSM. For women
aged under 40 years, this was predominantly apparent
for those with ALNI-negative breast cancer. An age of
80 years or more was a prognostic factor for high
BCSM, independent of stage and diagnostic period.
Strengths and limitations
This study was conducted among women diagnosed be-
tween 1961 and 1991 and due to this some information
of interest unfortunately could not be collected at the
time of diagnosis. However, to our knowledge this is one
of the largest population-based patient datasets with all
women treated at the same institution. It consisted of
4,453 women, with a 10-year follow-up period for the
entire cohort. No referrals were made to or from the
hospital for patients with breast cancer. All women diag-
nosed with invasive breast cancer in Malmö between
1961 and 1991 were included, minimizing a potential se-
lection bias. Age at diagnosis and breast cancer diagnosis
was obtained for all patients from the Swedish
Population Registry and the Swedish Cancer Registry.
Both these registries are highly valid [19,20].Histopathological examination was performed on all
samples at a single pathology department; hence the reli-
ability of tumor characteristics ought to have been high
[16]. Cause of death was obtained from the Swedish
Cause of Death Registry. The validity of the Swedish
Cause of Death Registry has been evaluated for cause of
death amongst breast cancer patients diagnosed in Malmö
in two studies and found to be highly accurate [16,21].
The most important data that we were not able to ad-
just for due to information not being collected were
histological grade, hormone receptor status, and adjuvant
treatment. Data on the type of operation and whether an
axillary dissection was performed is displayed in Table 1.
The results were stratified for diagnostic period, which
may have decreased the risk of confounding caused by
treatment. In all periods adjuvant therapy was in general
given routinely according to factors such as age, and
ALNI; factors that were included in the analysis. This may
have adjusted for treatment to some extent. However, it is
still likely that older women less frequently would have
been given adjuvant treatment according to the guidelines,
which would have led to a lower survival rate. This is dis-
cussed further in the section below on older women. Also,
women under 40 years may have been given more aggres-
sive treatment than the guidelines indicated. For young
women, it may therefore be the opposite, that is, they may
have been treated more actively using, for example,
chemotherapy, and their survival rate may have been even
lower if we had been able to adjust for treatment.
Young women
In the present study, young age (<40 years) was positively
associated with high BCSM following invasive breast can-
cer. In the second diagnostic period (1971 to 1980) the
BCSM of young women decreased and then increased



















1961-1970 <40 51 214 16 (18) 747 1.39 (0.79-2.45) 1.69 (0.96-2.98) 1.23 (0.69-2.20)
40-49 214 940 50 (56) 532 1.00 1.00 1.00
50-59 256 1,008 82 (88) 813 1.53 (1.07-2.17) 1.51 (1.06-2.16) 1.46 (1.00-2.11)
60-69 274 1,107 65 (93) 587 1.10 (0.76-1.59) 1.15 (0.79-1.67) 1.12 0-75-1.66)
70-79 189 673 45 (92) 669 1.25 (0.83-1.86) 1.33 (0.88-2.02) 1.35 (0.87-2.09)
≥80 108 252 29 (82) 1,151 2.10 (1.33-3.32) 1.39 (0.86-2.27) 1.21 (0.72-2.03)
All 1,092 4,193 287 (429) 684
1971-1980 <40 44 201 8 (10) 399 1.16 (0.54-2.51) 1.17 (0.54-2.55) 1.09 (0.50-2.39)
40-49 211 960 33 (39) 344 1.00 1.00 1.00
50-59 343 1,535 65 (76) 423 1.23 (0.81-1.87) 1.15 (0.75-1.77) 1.18 (0.76-1.82)
60-69 386 1,633 84 (116) 514 1.49 (1.00-2.23) 1.65 (1.09-2.48) 1.69 (1.11-2.57)
70-79 287 1,084 72 (122) 664 1.92 (1.27-2.90) 1.78 (1.16-2.72) 1.81 (1.17-2.81)
≥80 181 518 44 (119) 849 2.43 (1.55-3.82) 2.27 (1.38-2.73) 2.41 (1.44-4.02)
All 1,452 5,931 306 (482) 516
1981-1991 <40 69 307 16 (17) 521 1.45 (0.80-2.62) 1.49 (0.82-2.70) 1.15 (0.62-2.13)
40-49 205 946 34 (38) 359 1.00 1.00 1.00
50-59 287 1,258 48 (62) 382 1.06 (0.68-1.65) 1.30 (0.84-2.03) 1.33 (0.85-2.09)
60-69 402 1,819 55 (74) 302 0.84 (0.55-1.29) 0.85 (0.55-1.31) 0.90 (0.58-1.41)
70-79 342 1,389 60 (116) 432 1.20 (0.79-1.82) 0.67 (0.43-1.04) 0.82 (0.52-1.30)
≥80 270 837 57 (177) 681 1.88 (1.23-2.87) 0.79 (0.50-1.24) 1.06 (0.65-1.72)
All 1,575 6,557 270 (484) 412
CI = Confidence Intervals.
aBreast cancer-specific mortality per 10,000 person-years.
bAdjusted for tumor size, axillary lymph node status and distant metastasis.

























Figure 2 Age at diagnosis in relation to breast cancer-specific mortality/10,000 person-years with stratification for diagnostic period;
five-year follow-up period.
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However, it is difficult to interpret these small changes in
BCSM as only 44 women under 40 years were diagnosed
in the second period and chance may have caused some of
the change.
It has been shown that young women have higher
grade tumors, which are consequently more aggressive
[8,22,23]. Tumors in young women are also more prone
to be hormone receptor negative, which makes them less
susceptible to respond well to adjuvant endocrine ther-
apy such as tamoxifen [8,23]. Therefore the medical ad-
juvant therapy form for young women has instead been
chemotherapy (introduced in the late 1970s at this insti-
tution) [16]. However, according to the results of this
study, the BCSM of young women did not decrease in
relation to other age groups in spite of the introduction
of chemotherapy. Young women had the second highest
BCSM in the diagnostic period 1981 to 1991, following
the introduction of chemotherapy.
Several previous studies have also found young women
to have a higher BCSM than other age groups
[6-10,13,24-29]. However, two studies concluded that
there was no difference in survival rates between young
and middle-aged women [14,30]. The contradictory re-
sults may be due to breast cancer being a heterogeneous
disease, with the prognostic factor age only having an ef-
fect in certain subgroups of breast cancers, such as the
stage factors size, ALNI, and distant metastasis. A few
previous studies have stratified for stage to evaluate this,
with contradictory results. One study reported worse
survival rates for young women in stages I and II [10],
one large study for stages I to III [9], and one review
from 2008 concluded that a worse outcome for young
women is found in all stages (I to IV) [11].
Our analysis, stratified for ALNI, demonstrated that
the RR increase of young women was especially apparent
in ALNI-negative young women; ALNI-negative women
aged under 40 years had a worse prognosis than ALNI-
negative women in other age categories. As ALNI status
is the most important prognostic factor and women who
are diagnosed as ALNI-negative are expected to have a
favorable prognosis, this is an important finding. A rea-
son for our result could be that the strong confounding
factor ALNI had been stratified for, which may reveal a
relatively weak prognostic factor; young age. It can also
be because adjuvant treatments, such as radiotherapy,
chemotherapy, and endocrine treatment, were given
mainly to ALNI-positive women [16]. Consequently, the
outcome in ALNI-negative women would reveal the nat-
ural course of events, where young women were distin-
guished as having the very worst five-year prognosis out of
all age groups. In line with these findings, a previous study
has shown the poor prognosis of young women is only to
be found in those not treated with adjuvant therapy [29].In the sensitivity analysis, there was no large difference
in BCSM rate between women under 35 years and 35 to
39 years. However, the number of women diagnosed
who were under 35 years was small (53 women), hence
the statistical power of the analysis was poor.
Middle-aged women
Middle-aged women (50 to 69 years) had a worse sur-
vival rate than the reference group (40 to 49 years) in
the first two diagnostic periods. However, in the last
diagnostic period, starting in 1981, women aged 50 to
59 years had a similar survival rate and women aged 60
to 69 years had an even better survival rate, as compared
to the reference group. Mammographic screening was
introduced at this institution in 1976 in a randomized
trial, inviting 50% of women aged 45 to 69 to participate
[16]. We did not have information on which of the
breast cancer cases were detected by mammographic
screening. However, it is possible to hypothesize that this
may explain some of the decrease in BCSM over the
diagnostic periods, seen in women aged 50 to 59 years
and 60 to 69 years in this study, as they would have been
diagnosed at an earlier stage and subsequently have had
a longer time from diagnosis until potential death from
breast cancer (a lead time effect) [31]. On the contrary,
the youngest and oldest women may still have experi-
enced a relatively late diagnosis and, hence, a continuing
higher BCSM rate. Adjuvant therapy was also intro-
duced in the late 1970s. This may also be part of im-
proved survival rates for middle-aged women due to the
connection in time.
Elderly women
Women aged 70 to 79 years had a high BCSM until the
last diagnostic period. It may be that diagnosis and treat-
ment improved also for this age category, but slightly
later than for middle-aged women.
The strongest association for all age categories was for
the oldest women (≥80 years), who had a worse outcome
in all analyses. Previous studies have found contradictory
results, with old age being shown to be associated with
[5,12,13,32], as well as not associated with [4,14] a high
mortality rate. One large study even found elderly
women with ALNI-negative tumors to have a favorable
outcome [15]. Adjustment for stage at diagnosis made
the association slightly weaker in the present study, sug-
gesting the possibility of delayed diagnosis. However, the
results still remained statistically significant following
adjustment for stage. Furthermore, stratification for
ALNI did not have a large effect; therefore stage could
not explain the entire difference in BCSM rate.
The survival rate for elderly women improved over the
diagnostic periods. A reason for this may be that tumors
Brandt et al. World Journal of Surgical Oncology  (2015) 13:33 Page 10 of 11in elderly women are often hormone receptor positive
[15]. Hence a high percentage of this age group responds
well to endocrine therapy [33,34]. The endocrine therapy
tamoxifen was introduced in 1978 at this institution and
could have contributed to this improved survival rate [16].
Although the survival rate improved for elderly
women over the diagnostic periods, elderly women con-
tinued to have a higher relative risk when compared to
other age categories. This could be due to elderly
women potentially not receiving treatment according to
the guidelines. In this material we unfortunately did not
have access to data on adjuvant therapy, but we did have
information on type of operation and data on whether
or not an axillary dissection was performed. This indeed
showed that it was more common that older women had
been regarded as unsuitable for surgery and an axillary
dissection was also less common in these women. Fur-
thermore, it has been displayed in previous studies that
women have not received treatment according to the
guidelines, especially regarding adjuvant radiotherapy
[12,15,35-38]. Other studies have also shown axillary
lymph node dissection to be less frequently performed
in the elderly [5,36,38]. Comorbidity can naturally lead
to elderly women receiving less aggressive treatment,
but studies have shown that old age is an independent
risk factor for not receiving appropriate therapy after
control for comorbidity [12].
Conclusions
In this study, young (<40 years) and old (≥80 years) age
was positively associated with a high BCSM. For women
aged under 40 years, this association was predominantly
apparent for those with ALNI-negative breast cancer.
An age of 80 years or more was a prognostic factor for
high BCSM, independent of stage and diagnostic period.
Breast cancer is rare amongst young women, but it is
still the most common malignancy in women under
40 years of age [2]. In this study, mortality in ALNI-
negative young women was higher than for ALNI-
negative women of other age categories. This motivates
further studies evaluating if ALNI-negative young
women have a poor prognosis.
In this study, an age of 80 years or more was a
prognostic factor for high BCSM, independent of stage
and diagnostic period. Approximately one third of breast
cancer is diagnosed in women aged 70 years or more, and
around 15% of all breast cancer occurs in women who are
aged 80 years or more at the time of diagnosis [2]. With
average life expectancy rising, breast cancer is likely to be-
come increasingly frequent in elderly women [39]. Elderly
women will also live longer from the time of diagnosis and
subsequently have an increased risk of metastasis. Hence,
it is important to make sure that elderly women also re-
ceive treatment according to the guidelines.Consent
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